Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07572123CT.gov Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07275216CT.gov Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | — | Recruiting | — | — | — |
NCT07021989CT.gov ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06916416CT.gov Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06377540CT.gov MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06504394CT.gov A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) | — | Active Not Recruiting | — | — | — |
NCT04838652CT.gov Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06164275CT.gov Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05711628CT.gov A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
Show 15 more trialsShow fewer
NCT05404945CT.gov Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | — | Active Not Recruiting | — | — | — |
NCT04788043CT.gov Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04510636CT.gov Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT05179603CT.gov A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | — | Terminated | — | — | — |
NCT05008224CT.gov Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | — | Completed | — | — | — |
NCT04187872CT.gov LITT and Pembrolizumab in Recurrent Brain Metastasis | — | Terminated | — | — | — |
NCT03331341CT.gov Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03236935CT.gov Phase Ib of L-NMMA and Pembrolizumab | — | Completed | — | — | — |
NCT03471351CT.gov Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | — | Terminated | — | — | — |
NCT03226249CT.gov PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03150329CT.gov Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | — | Active Not Recruiting | — | — | — |
NCT02981914CT.gov Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02332668CT.gov A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Classic Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | National Cancer Institute (NCI) | P3 | BB · 65 |
| Dacarbazine | City of Hope Medical Center | P3 | BB |
| Etoposide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Adriamycin | Michael Spinner, MD | P3 | BB |
| Vinblastine | University of Washington | P2 | BB |
| Tislelizumab | Children's Cancer Group, China | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Brentuximab Vedotin | National Cancer Institute (NCI) | P3 | BB |
| Gls-010 | Guangzhou Gloria Biosciences Co., Ltd. | P3 | BB |
+42 more in the Classic Hodgkin Lymphoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Classic Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-classic-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →